Basil Systems Nets $11.5M to Advance its AI-Powered Lifecycle Management Platform

Basil Systems has raised $11.5 million in funding led by Golden Ventures, with participation from Hearst Ventures and Argosy Capital, to expand its enterprise BasilIntel SaaS platform, deepen product capabilities, and accelerate the deployment of data-driven insights across the pharmaceutical and medical device industry.

The new funding will enable Basil to expand its data coverage, onboard additional enterprise clients, and expand the rollout of artificial intelligence (AI) and machine learning to automate high-stakes, high-complexity workflows. The company plans to broaden its support to adjacent players across the life sciences ecosystem, including drug and device manufacturers, suppliers, clinical research organizations, and regulatory agencies.

“Basil Systems is transforming how life sciences companies access and act on regulatory intelligence,” said Bert Amato, venture partner, Golden Ventures and board director. “What once took teams weeks or months of manual effort using disconnected systems, Basil now delivers in real time by providing actionable insights that drive better product decisions, mitigate risk, and accelerate approvals. This isn’t just a workflow improvement, it’s a fundamental shift in how healthcare innovation gets to market.”

Life sciences companies face complex, mission-critical operations that are still burdened by manual workflows, siloed data, and outdated tools. From regulatory submissions and clinical planning to post-market surveillance and competitive analysis, critical decisions are often made without clear, timely insight. Basil Systems changes that by delivering real-time, AI-powered intelligence that helps teams move faster, collaborate, reduce risk, and make smarter decisions across product development, regulatory strategy, and market execution.

Basil has built the largest indexed dataset in life sciences, BasilLink, with more than 600 million records continuously updated, structured, and growing. This includes regulatory submissions, global drug labels, clinical trials, adverse event reports, guidances, regulations, recalls, citations, inspections, and more.

Its proprietary platform delivers answers to complex questions in seconds, such as identifying which materials are most often linked to knee implant failures or comparing label changes across oncology therapies in specific patient populations. These insights are accessible through a full-text natural language interface, with API connectivity and enterprise-grade infrastructure designed to support millions of concurrent users.

“Basil Systems has built the most comprehensive, structured dataset in life sciences, with over 600 million records spanning regulatory filings, clinical trials, post-market events, drug labels, and more,” Basil Systems Founder/CEO Anthony Cirurgiao stated. “Our AI-powered platform transforms that data into real-time answers for the strategic questions that drive product success. We’re not just accelerating workflows and decision making, but creating a new standard for how life sciences companies make critical decisions across innovation, regulatory, safety and commercialization.”

The BasilIntel platform is already used by four of the five largest global medical device companies and is in active trials with three of the top global pharmaceutical firms.

Life sciences companies often struggle with fragmented, siloed data spread across departments and formats, which slows down critical regulatory and product decisions. While many solutions promise to fix this, they’re often too complex or unreliable. Basil Systems takes a streamlined, proven approach by using proprietary machine learning algorithms to automatically ingest and unify scattered data into a single, fully indexed source of truth. The result is faster access to insights, leaner operations, and a scalable foundation for AI-driven decision-making across the enterprise.

“Basil has built a centralized intelligence engine for how medical products are developed, approved, and perform in-market,” said Mohamed Shariff, director of Regulatory Affairs, Johnson & Johnson. “With unmatched depth in regulatory and real-world life sciences data, Basil gives companies the visibility and analytics they need to make faster, smarter decisions. It’s becoming the default infrastructure layer for data-driven strategy in life sciences.”

In addition to core regulatory and clinical insights, Basil’s platform is used for strategic product development, supply chain optimization, risk mitigation, and real-world evidence (RWE) analysis. It supports use cases across regulatory, clinical, quality, medical affairs, and commercial divisions to provide a unified system of record and intelligence.

Basil Systems delivers an AI-powered SaaS platform transforming the way in which pharmaceutical and medtech companies manage regulatory, clinical, and product lifecycle strategy. By structuring the world’s largest indexed database of regulatory, drug, device, and post-market data, Basil helps life sciences organizations accelerate development, reduce risk, and improve product performance. Basil turns complex data into actionable insights that drive better decisions and better patient outcomes.